MARKET

ALT

ALT

Altimmune
NASDAQ
3.130
+0.180
+6.10%
Opening 15:42 08/21 EDT
OPEN
2.980
PREV CLOSE
2.950
HIGH
3.240
LOW
2.950
VOLUME
5.20M
TURNOVER
--
52 WEEK HIGH
6.44
52 WEEK LOW
2.560
MARKET CAP
608.84M
P/E (TTM)
-4.0361
1D
5D
1M
3M
1Y
5Y
1D
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
NASDAQ · 2d ago
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
NASDAQ · 2d ago
Altimmune Maintained at Buy as Late-Stage Liver Programs Advance and $20 Price Target Remains Unchanged
TipRanks · 4d ago
Altimmune reports Q2 EPS (12c), consensus (12c)
TipRanks · 4d ago
Weekly Report: what happened at ALT last week (0810-0814)?
Weekly Report · 4d ago
Marathon, Phillips 66, Clean Energy Fuels, Altimmune, Eaton Insider Shake‑Up
TipRanks · 6d ago
Altimmune: Pemvidutide Performs, But A Long Wait Ahead
Seeking Alpha · 08/13 17:48
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
NASDAQ · 08/13 16:14
More
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.